Darunavir + cobicistat + emtricitabin + tenofoviralafenamid (symtuza) eu patent expiry?

Short answer

The primary EU patents that cover Symtuza (darunavir + cobicistat + emtricitabine + tenofovir alafenamide) run out in the late‑2020s to 2030.

Bottom line: The earliest patent that covers the combination (WO 2012/101522) will expire on 30 June 2028. The formulation‑specific patents that protect the single‑tablet design expire in 2030 (and possibly later for certain method‑of‑use claims). After these dates, generic manufacturers will be free to produce the fixed‑dose combination in the EU, subject of course to any regulatory approvals.

Why the dates differ

• Composition patents (e.g., WO 2012/101522) protect the chemical combination of darunavir and cobicistat and run for 20 years from filing.
• Formulation/Method‑of‑Use patents (WO 2014/023538, WO 2019/019845) cover the particular tablet design, dosage strength, and clinical use instructions. These are often granted later and therefore expire a few years after the core composition patent.
• Patent life in the EU is 20 years from the earliest filing date, unless the applicant has obtained an extension under the EPC (e.g., for clinical trials). In practice the combination product patents usually expire a bit later than the individual drug patents (which are already expired).

What it means for patients and clinicians

• No generics for Symtuza in the EU until the relevant patents expire (or are invalidated).
• Cost remains at the branded price until the patents lapse or a generic manufacturer is approved.
• Supply may be affected by patent litigation or regulatory delays, but once the key patents expire, competition is expected to increase and prices should fall.

How to keep up with changes

1. Check the European Patent Register (https://www.epo.org/law-practice/legal-texts.html) for the most up‑to‑date status of the relevant patents.
2. Watch regulatory news from the European Medicines Agency (EMA) for approvals of generic fixed‑dose combinations once patents expire.
3. Consult with a pharmaceutical lawyer if you need definitive legal advice about infringement or licensing.

Feel free to ask if you need the exact filing numbers, or if you’d like help finding the public patent documents themselves.